Drug Search Results
More Filters [+]

Cixutumumab

Alternative Names: cixutumumab, imc-a12
Latest Update: 2024-04-02
Latest Update Note: Clinical Trial Update

Product Description

A fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cixutumumab)

Mechanisms of Action: IGF Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cixutumumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Peripheral Neuroectodermal Tumors, Primitive|Leiomyosarcoma|Synovial Sarcoma|Sarcoma, Ewing|Head and Neck Cancer|Squamous Cell Carcinoma|Adenocarcinoma|Primitive Neuroectodermal Tumors|Prostate Cancer|Rhabdomyosarcoma|Hepatocellular Carcinoma|Non-Small-Cell Lung Cancer|Uveal Melanoma|Male Breast Cancer|Pancreatic Cancer|Gliosarcoma|Colorectal Cancer|Liver Cancer|Osteosarcoma|Soft Tissue Cancer|Esophageal Cancer|Hemangiosarcoma|Peritoneal Cancer|Neurofibrosarcoma|Liposarcoma|Alveolar Rhabdomyosarcoma|Alveolar Soft Part Sarcoma|Embryonal Rhabdomyosarcoma|Large Cell Carcinoma|Neuroendocrine Carcinoma|Adrenocortical Carcinoma|Kidney Cancer|Wilms Tumor|Embryonal Carcinoma|Neuroblastoma|Hepatoblastoma|Breast Cancer|Mesothelioma|Neuroendocrine Tumors|Retinoblastoma|Bronchiolo-Alveolar Adenocarcinoma|Gastrointestinal Cancer|Small Cell Lung Cancer

Phase 1: Thrombocytopenia|Oncology Solid Tumor Unspecified|Hyperglycemia|Insulinoma|Islet Cell Carcinoma|Glucagonoma|Neuroendocrine Tumors|Anemia|Hypertension|Paraganglioma|Pancreatic Cancer|Somatostatinoma|Carotid Body Tumor|Medullary Carcinoma|Carcinoma, Merkel Cell|Carcinoid Tumor|Neuroendocrine Carcinoma|Neutropenia|Malignant Carcinoid Syndrome|Gastrinoma|Gastrointestinal Cancer|Sarcoma, Ewing|Primitive Neuroectodermal Tumors|Peripheral Neuroectodermal Tumors, Primitive|Pinealoma|Hepatocellular Carcinoma|Glioma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCI-2011-03039

P2

Completed

Squamous Cell Carcinoma|Head and Neck Cancer

2018-08-15

NCI-2011-01917

P2

Completed

Small Cell Lung Cancer

2016-11-15

10-C-0146

P2

Completed

Mesothelioma|Peritoneal Cancer

2016-08-13

A Study in Non-Small Cell Lung Cancer

P2

Completed

Squamous Cell Carcinoma

2016-06-10

Recent News Events